

**ASX ANNOUNCEMENT**

**COMMENCEMENT OF THE TRADING OF RIGHTS ON THE ASX  
ASX: CDYR**

**SYDNEY, Wednesday, 10 March 2021: Cellmid Limited (ASX: CDY)** is pleased to advise that the rights in relation to the Company's Renounceable Rights Issue announced on 8 March 2021 have commenced trading today under the ASX code **CDYR**. Under the Rights Issue timetable, rights trading will end on 19 March 2021.

Approved for release by the Board of Directors.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

**Cellmid Limited (ASX: CDY)**

Cellmid is a health and beauty-tech business growing shareholder value through the development, global distribution and sales of its proprietary brands of differentiated, clinically validated longevity and anti-aging solutions. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated products for hair, skin and body. For further information, please see [www.cellmid.com.au](http://www.cellmid.com.au) and [www.evolisproducts.com.au](http://www.evolisproducts.com.au).

**Forward looking statements**

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the availability of resources, regulatory environment, the results of marketing and sales activities and competition.